Non-Chemo Regimen Led to High Response Rates in Cisplatin-Ineligible Bladder Cancer
PARIS — Nearly two-thirds of patients with untreated cisplatin-ineligible advanced urothelial cancer responded to an antibody-drug conjugate (ADC) and immunotherapy, a small randomized study showed. Overall, 49 of 76 patients responded to frontline enfortumab vedotin (EV; Padcev) and pembrolizumab (Keytruda), including eight complete responses. An additional 17 patients had stable disease, resulting in a clinical […]
Long-Term ADT With Radiation Helps Prevent Post-Prostatectomy Metastases
PARIS — In men undergoing radiotherapy after radical prostatectomy, 2 years of androgen deprivation therapy (ADT) improved outcomes when compared with a shorter course of ADT, according to results from the RADICALS-HD trial. At a median follow-up of more than 9 years, investigators found that the longer ADT duration improved metastasis-free survival (MFS) compared with […]
Triplet in First-Line Kidney Cancer Thwarts Disease Progression
PARIS — Adding the tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) to dual immune checkpoint inhibition improved progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), the phase III COSMIC-313 trial found. Among 550 patients with untreated intermediate- or poor-risk disease, those treated with the triplet therapy had a median PFS that was not […]
Three Adjuvant Immunotherapy Trials Flop in Renal Cell Carcinoma
PARIS — While pembrolizumab (Keytruda) has been approved as an adjuvant treatment for patients with high-risk renal cell carcinoma (RCC), three phase III studies presented at the European Society for Medical Oncology (ESMO) annual congress here failed to support the immune checkpoint inhibitor in this setting. In Part A of the CheckMate-914 trial, the median […]
‘Potential New Standard’ for Progressing Desmoid Tumors
PARIS — Progression-free survival (PFS) was significantly prolonged in patients with progressing desmoid tumors treated with an investigational gamma secretase inhibitor in a phase III trial. In the international DeFi study of more than 140 patients, risk for disease progression or death was reduced by 71% in the group randomized to nirogacestat, with a median […]
Targeted Combo Flops as First-Line Treatment in Advanced Breast Cancer
PARIS — A novel combination failed to improve the clinical benefit rate (CBR) in advanced triple-negative breast cancer (TNBC) compared with chemoimmunotherapy, a randomized trial showed. Adding the anti-CD73 antibody oleclumab to durvalumab (Imfinzi) and chemotherapy led to clinical benefit (response plus stable disease) in 43% of patients by 24 weeks as compared with 44% […]
Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials
PARIS — Olaparib (Lynparza) maintenance therapy appears to offer a long-term overall survival (OS) benefit for women with ovarian cancer, according to two phase III studies presented at the European Society for Medical Oncology (ESMO) annual congress. At 7 years in the SOLO-1 trial, 67% of patients with advanced BRCA-mutated ovarian cancer treated with the […]
Special Shielding Could Fix Cath Lab Staff’s Radiation and Orthopedic Issues
PARIS — An operator shielding system offered body protection rivaling that of standard lead gowns in the catheterization lab, providing a glimpse at a potential tantalizing future where interventional cardiologists can ditch their heavy gear without sacrificing radiation protection. At a center in Australia, an experiment showed that the Rampart shielding system — an adjustable […]
Paris Climate Agreement goal still within reach, suggests new study
The Paris Climate Agreement goal to limit global warming this century to 3.6 degrees Fahrenheit (2 degrees Celsius) over pre-industrial temperatures is still within reach, while apocalyptic, worst-case scenarios are no longer plausible, suggests a new CU Boulder analysis. Out today in Environmental Research Letters, the new study finds that a subset of climate scenarios […]
Visibly transparent radiative cooler under direct sunlight
Since the Paris Climate Agreement that took effect in 2016, 121 countries have pledged to become carbon neutral by 2050 as the world tries to reduce its fuel consumption. The Korean government also unveiled its 2050 Carbon Neutral Strategy on December 7, 2020 and declared Carbon Zero, making transition to new and renewable energy a […]